U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 430156,403USPC 10/535,232

APPLICANTS
INFORMATION DISCLOSURE STATEMENT Young Min Kim et al.

GROUP ART UNIT 1644

U.S. PATENT DOCUMENTS

FILING DATE

June 19, 2006

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,045,312	09/03/91	Aston et al.	424	179.1	
	AB	5,116,964 A1	05/26/92	Capon et al.	536	23.5	
	AC	5,349,053 A1	09/20/94	Landolfi	530	351	
	AD	5,585,097 A1	12/17/96	Bolt et al.	424	133.1	
	AE	5,605,690 A1	02/25/97	Jacobs et al.	424	134.1	
	AF	5,672,688 A1	09/30/97	Kobayashi et al.	530	391.7	
	AG	5,712,121 A1	01/27/98	Devos et al.	435	69.7	
	AH	5,723,125 A1	03/03/98	Chang et al.	424	134.1	
	ΑI	5,908,626 A1	06/01/99	Chang et al.	424	134.1	
	AJ	5,977,310 A1	11/02/99	Namiki et al.	530	351	
	AK	6,030,613 A1	02/29/00	Blumberg et al.	424	134.1	
	AL	6,277,375 B1	08/21/01	Ward	424	133.1	
	AM	6,340,742 B1	01/22/02	Burg et al.	530	351	
	AN	6,410,008 B1	06/25/02	Strom et al.	424	85.2	
	AO	6,444,792 B1	09/03/02	Gray et al.	530	387.3	
	AP	6,451,313 B1	09/17/02	Maddon et al.	424	185.1	
	AQ	6,475,983 B1	11/05/02	Eid et al.	514	2	
	AR	6,620,413 B1	09/16/03	DeSauvage et al.	424	178.1	
	AS	6,660,843 B1	12/09/03	Feige et al.	530	391.7	
	AT	2001/0053539A1	12/20/01	Lauffer et al.	435	69.7	
	AU	2002/0037558 A1	03/28/02	Lo et al.	435	69.6	
	AV	2002/0081664 A1	06/27/02	Lo et al.	435	69.5	
	AW	2003/0073164 A1	04/17/03	Simmons et al.	435	69.1	
	AX	2003/0082679 A1	05/01/03	Sun et al.	435	69.1	
	AY	2003/0082749 A1	05/01/03	Sun et al.	435	70.21	

EXAMINER DATE CONSIDERED

										Class C	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					ATTY. DOCKET NO. APPLICATION NO. 430156.403USPC 10/535,232			ICATION NO.	Sheet 2	2_OI_3	
				APPLICANTS Young Min Kim et al. FILING DATE GROUP ART UNIT							
				II C	DATENT	June 19, 2006		1644	4		
EXAMINER INITIAL						CLASS SUBCLASS		FILING DATE IF APPROPRIATE			
	AA	200	4/0044188 A1	03/04/04	Feige et a	1.	530 388.23		388.23		
	AB	200	4/0053845 A1	04/18/04	Feige et a	1.	514 12		12		
				FOREI	GN PATE	NT DOCUMENTS					
			DOCUMENT NUMBER	DATE		COUNTRY				TRANS	LATION
	AC	0 -	464 533 B1	01/08/92	EP (+ Eng	P (+ English Abstract)					X
	AD	0 .	580 171 A2	01/26/94	EP						
	AE	62	2-201582	09/05/87	JP (+ English Abstract)					X	
	AF	10	-0249572 B1	12/27/99	KR (+ English Abstract)					X	
	AG	10	-0316347	11/20/01	KR (+ English Abstract)					X	
	AH	20	03-0009464 A1	01/29/03	KR (+ English Abstract)				X		
	AI	97	7/24137 A1	07/10/97	wo						
	AJ	99	/02709 A1	01/21/99	wo						
	AK	00)/23472 A2	04/27/00	wo						
	AL	00	/40615 A2	07/13/00	wo						
	AM	00	/69913 A1	11/23/00	wo						
	AN	01	/03737 A2	01/18/01	wo						
	AO	01	/83527 A2	11/08/01	wo						
	AP 03/077834 A2 09/25/03 WO										
			ОТНІ	ER PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.))			
AQ Bentz et al., "Improved local delivery of TGF-β2 by binding to injectable fibrillar collager via difunctional polyethylene glycol," J. Biomed. Mat. Res. 39(4):539-548, 1998.							lagen				

Champman, "PEGylated antibodies and antibody fragments for improved therapy: A AR review." Advanced Drug Delivery Reviews 54(4):531-545, June 17, 2002. EXAMINER DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				Sheet 3 of 3						
		U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	APPLICATION NO.						
		PATENT AND TRADEMARK OFFICE	430156,403USPC	10/535,232						
			APPLICANTS							
	INFOR	MATION DISCLOSURE STATEMENT	Young Min Kim et al.							
		(Use several sheets if necessary)	FILING DATE	GROUP ART UNIT						
			June 19, 2006	1644						
		OTHER PRIOR ART (Including								
	AA	Matsuda et al., "Proton nuclear magnetic resonance studies of the structure of the Fc								
		fragment of human immunoglobulin G1: comparisons of native and recombinant proteins,"								
		Molecular Immunology 27(6):571-5	580, 1990.							
		Stevenson et al. "Conjugation of human Fey in closed-hinge or open-hinge configuration to								
	AB Stevenson et al. "Conjugation of human Feγ in closed-ninge or open-ning Fab'γ and analogous ligands," <i>Journal of Immunology 158</i> :2242-2250, Ja									
	AC	van der Poll et al., "Effect of a Reco	mbinant Dimeric Tumor Ne	ecrosis Factor Receptor on						
	Inflammatory Responses to Intravenous Endotoxin in Normal Humans," Blood									
		89(10):3727-3734, May 15, 1997.								
		, , , , , , , , , , , , , , , , , , , ,								
	AD									
	\vdash									
	AE									
	AF									
	Ai									
	AG									
	AH									
	AI									
	Ai									
	AJ									
	\vdash									
	AK									
	AL									
	\vdash	-								
	AM									
	AN									
	ZALS									
	AO									
	\vdash									
	AP									
EXAMINE	-R		DATE CONSIDERED							
EXAMIN	ER: 1	nitial if reference considered, whether or not citation is in co	nformance with MPEP 609. Draw line the	rough citation if not in						

conformance and not considered. Include copy of this form with next communication to applicant.